Belgium
Confo Therapeutics, founded in 2015 and headquartered in Belgium, is a pioneering biotechnology company that leverages its proprietary technology platform to stabilize functional conformations of GPCRs (G protein-coupled receptors). This innovative approach uncovers a vast array of previously inaccessible GPCRs as potential drug targets, setting the stage for significant advancements in drug discovery.
The company’s cutting-edge technology, combined with deep pharmacologic and biologic insights, is pivotal in developing a diverse pipeline of drug candidates. These candidates have the potential to revolutionize therapeutic outcomes for patients suffering from severe illnesses that currently lack disease-modifying treatments.
Confo Therapeutics emerged from the esteemed Vrije Universiteit Brussel (VUB) and VIB, benefiting from Belgium's vibrant scientific ecosystem. Backed by international life-science investors, its team comprises seasoned professionals with prolific backgrounds in biopharmaceuticals, positioning the company for impactful growth in the healthcare industry.
